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Editorial on the Research Topic
Regulation of Soluble Immune Mediators by Non-Coding RNAs
Non-coding RNAs (ncRNAs), defined as transcripts that do not encode proteins, are known since
long time for their role in translation (i.e. transfer RNAs, ribosomal RNAs) and in splicing events
(i.e. small nuclear and small nucleolar RNAs). However, only recently, the revolutionary advances in
deep sequencing technology brought to light several new classes of ncRNA, classified according to
their length into “short” ncRNAs (<200 nucleotides, that includes piwi-associated RNAs,
endogenous short-interfering RNAs, microRNAs, Y-RNAs and others), and “long” ncRNAs
(lncRNAs, >200 nucleotides) (1).
Cytokines are crucial soluble messengers of the immune system that regulate and sustain
inflammation and immunity. Cytokine expression is tightly regulated, reflecting the need of the
immune system to tailor the magnitude and duration of its responses to induce pathogen clearance,
but not tissue damage. Thus, understanding cytokine regulation is crucial to gain insight and
eventually manipulate undesired immune responses.
In this Research Topic, 53 authors contributed 11 articles touching on many of the combined
roles of ncRNAs on the production of cytokines and their consequential effect on cytokine-related
functional outputs, as well as inflammatory/autoimmune pathologies.IMMUNE REGULATION BY INTRACELLULAR ncRNAS
Other than the size limit of 200 nt and a lack of protein-coding potential, the sole other common
feature of all ncRNAs consists in being functionally implicated in gene regulatory processes. This is
achieved via a multitude of mechanisms, ranging from promoter-specific repression, transcriptional
activation, epigenetic remodeling, or post-transcriptional gene regulation such as translational
blockade and/or activation (1). Based on these features, the regulatory functions of ncRNAs are
recognized to be involved in virtually all homeostatic, developmental and reactive pathways and
systems, including the immune response (2, 3).org October 2020 | Volume 11 | Article 6072221
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the best characterized post-transcriptional regulators of cytokine
production. In this Research Topic, Garavelli et al. review the
literature concerning regulation of adaptive cytokines by
miRNAs, while Salvi et al. concentrate on miRNA-dependent
regulation of cytokines that are hallmarks of autoimmune
diseases. The emerging picture is quite complicated for several
reasons. First, the final effect on cytokine levels may derive by
direct regulation of cytokine RNA or by the modulation of
cytokine inducers or repressors. In addition, as these authors
underline, the coordinated induction and modulation of tens of
miRNAs may be required to efficiently affect the components of a
genetic network. Thus, it is crucial to rapidly break away from
the musty assumption “one miRNA, one cytokine” to boldly
embrace the “rheostat” function of miRNAs and to be able to
frame the mechanistic miRNA regulation in process-specific
contexts. One example of such “integrated view” is beginning
to emerge in the multifaceted crosstalk between cell activation,
ncRNAs and cytokine expression (Figure 1).
Toll-like receptors (TLRs) are key pathogen receptors of the
innate immune system. The first miRNA described as induced
following TLR activation and controlling TLR signaling through
a negative feedback regulation loop dates back to 2006 (4). Since
then, our knowledge on the miRNAs induced upon cell
activation downstream TLRs and on the mechanisms through
which these miRNAs feedback modulate immune cell responses
has grown enormously. More recently, a number of lncRNAs
have been included among the non-coding transcripts with
regulatory functions in the TLR signaling pathway. Three
reviews of this Research Topic are focused on the role of
ncRNA in immune cell activation downstream TLRs and on
the pathologies driven by dysregulation of the TLR-induced
responses. Bayraktar et al. summarize the potential role ofFrontiers in Immunology | www.frontiersin.org 2miRNAs in regulation of gene expression and TLR signaling,
with a focus on the ability of miRNAs to act as endogenous
ligands of specific TLRs and trigger the downstream immune
response (see further). The complexity of this highly regulated
network of ncRNAs in macrophage biology is further discussed
by Curtale et al., with particular emphasis on the role of miRNAs
in macrophage heterogeneity and plasticity in response to
environmental cues, bacterial infection, tissue regeneration and
endotoxin tolerance. Further studies on TLR-induced miRNAs
and lncRNAs in the regulation of endotoxin tolerance are
comprehensively reviewed by Vergadi et al., and their impact
in the context of innate immune tolerance and of sepsis is
discussed. Together with the abovementioned reviews, an
original article by Mariotti et al. identifies a role for a lncRNA
(namely NRIR) in the expression of type I Interferon Stimulated
Genes (ISGs) in monocytes downstream TLR4 activation.
Remarkably, this study highlights that aberrant expression on
NRIR can be involved in the dysregulation of the innate immune
system linked to the development of Systemic Sclerosis.IMMUNE REGULATION AND BIOMARKER
FUNCTION OF EXTRACELLULAR ncRNAS
The picture of immune regulation by ncRNAs is further
complicated by their travelling in extracellular spaces, either
encapsulated in extracellular vesicles (EVs) or associated to
macromolecular structures such as ribonucleoproteins and
lipoprotein particles. Despite the function of most extracellular
ncRNAs remains largely elusive, they are in the scientific
limelight because of a possible role as regulators of intercellular
communications as well as a tremendous potential as non-FIGURE 1 | Multifaceted crosstalk between cell activation, ncRNAs, and cytokine expression (see text).October 2020 | Volume 11 | Article 607222
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of the immune system (5).
Such burning interest well reflects in our Research Topic, where
five contributions deal with different aspects of extracellular
ncRNAs biology. Turchinovitch et al. provide a state-of-the-art
overview of the transcriptome of EV-associated RNAs, where
miRNAs represent the most intensively studied component and,
at the same time, the minority of all EV-enclosed RNAs. One
prominent class of EV-associated extracellular RNAs involved in a
range of immune-mediated processes are the Y-RNAs, discussed
here by Driedonks and Nolte-’t Hoen. Both these reviews also
address some technical challenges associated with obtaining pure
EVs and deep sequencing of the EV-associated RNAs, as well as in
assessing whether extracellular ncRNAs are contained in
ribonucleoprotein complexes or EVs. These technical aspects are
crucial to overcome the frequently observed inconsistency in the
identification and quantification of extracellular ncRNAs, which
currently impairs our capacity to use them as reliable biomarkers.
Both these reviews, as well as other contributions (Garavelli
et al.; Salvi et al.; Bayraktar et al.; Zitzer et al.), also converge in
highlighting a role for extracellular ncRNAs as ligands of RNA
sensors, TLRs in particular. This function was recently
demonstrated for EV-associated miRNAs (6) and may play a
role in inducing unwanted inflammation and tissue damage, as
reviewed here by Zitzer et al. In this regard, based on the largely
sequence-independent impact of nucleic acids on the TLRs (6),
Turchinovitch et al. and Driedonks and Nolte-’t Hoen point out
the strong possibility that more abundant non-miRNA classes
could significantly contribute to such activation.THERAPEUTING EXPLOITATION OF
ncRNAS
It is not surprising tofindderegulated ncRNAs asmajor contributors
of cytokine-driven pathologies ranging from acute graft-versus-host
disease, autoimmune diseases, Systemic Sclerosis, compensatory
Anti-inflammatory Response Syndrome (CARS), endotoxin
tolerance and sepsis, as showcased in this Research Topic.
The other side of this same coin would consist of therapeutical
exploitation of ncRNAs. Our current lack of a full understanding of
their biology and of the intricate network of interactions with the
human genome, transcriptome and proteome restrains the
translation of such strategies into the clinical use. In addition, a
number of specific challenges associated with ncRNA targeting stillFrontiers in Immunology | www.frontiersin.org 3need to be addressed, such as predicting possible off-target effects and
toxicity, improving stability and optimizing the delivery systems (7).
In this regard, the original contribution by Macleod et al. focuses on
the prevention of paradoxic inflammation following topical delivery
of RNA aptamers to treat inflammatory skin diseases.
Despite these knots to be solved, a number of miRNA-based
therapeutic tools, mainly for cancer management, entered the
clinical trial in the last 5 years (8). Here, one original work by
Kim et al. propose miR-135-5p as a target for the development of
anti-allergic drugs based on its capability to interact with p62, a
selective receptor of autophagy.CONCLUDING REMARKS
As a result of almost two decades of extensive investigations,
nowadays miRNAs can be listed among the soluble mediators of
the immune response. In addition, more ncRNAs promise to
hold the scene in the near future and for a long time. As we gain
more knowledge about the exciting properties of ncRNAs,
however, we also get aware of the intricacy of the emerging
picture. Figure 1 schematizes how the bidirectional interplay
between cytokine-modulated ncRNAs expression and, in turn,
ncRNAs-driven control of cytokine expression and production is
further complicated by the recent discovery of the ability of
ncRNAs to trigger activation of specific immune receptors. The
scrupulous untangling of this intricate web will allow to fully
exploit he tremendous potential of ncRNAs as biomarkers and
therapeutic tools to safely redirect undesired immune responses.AUTHOR CONTRIBUTIONS
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